<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Shuttle Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc</link>
<description>Latest news and press releases for Shuttle Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/shuttle-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c13c78dffbe2df118d20.webp</url>
<title>Shuttle Pharmaceuticals Inc</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc</link>
</image>
<item>
<title>RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/retransmission-shuttle-pharmaceuticals-launches-autonomous-self-reasoning-ai-agent-for-scientific-workflows</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/retransmission-shuttle-pharmaceuticals-launches-autonomous-self-reasoning-ai-agent-for-scientific-workflows</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Gaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today</description>
</item>
<item>
<title>Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-launches-autonomous-self-reasoning-ai-agent-for-scientific-workflows</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-launches-autonomous-self-reasoning-ai-agent-for-scientific-workflows</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today</description>
</item>
<item>
<title>Shuttle Pharmaceuticals Announces $3.5 Million Public Offering</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-dollar35-million-public-offering-35</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-dollar35-million-public-offering-35</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>Gaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the</description>
</item>
<item>
<title>Shuttle Pharmaceuticals Acquires AI Health Platform</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-acquires-ai-health-143000441</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-acquires-ai-health-143000441</guid>
<pubDate>Fri, 21 Nov 2025 14:30:00 GMT</pubDate>
<description>Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired...</description>
</item>
<item>
<title>Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-above-market-120000411</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-above-market-120000411</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>Gaithersburg, Maryland--(Newsfile Corp. - November 3, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced that it entered into a securities purchase agreement with a single investor for aggregate gross proceeds of approximately $2.5 million (the "Offering"), before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for marketing,...</description>
</item>
<item>
<title>Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH) </title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-positions-to-become-the-first-self-learning-biotech-after-definitive-loi-to-acquire-moleculeai-nasdaqshph</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-positions-to-become-the-first-self-learning-biotech-after-definitive-loi-to-acquire-moleculeai-nasdaqshph</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Artificial intelligence has reshaped nearly every industry, but drug discovery has always been its</description>
</item>
<item>
<title>Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-acquire-ai-molecular-200500478</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-acquire-ai-molecular-200500478</guid>
<pubDate>Tue, 21 Oct 2025 20:05:00 GMT</pubDate>
<description>Rockville, Maryland--(Newsfile Corp. - October 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has entered into a binding term sheet with 1542770 BC Ltd. ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, Shuttle or one of its affiliates will acquire substantially all of Molecule's assets and liabilities for a total..</description>
</item>
<item>
<title>Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-turns-radiation-into-a-smart-weapon-with-definitive-loi-for-moleculeai-nasdaqshph</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-turns-radiation-into-a-smart-weapon-with-definitive-loi-for-moleculeai-nasdaqshph</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. It</description>
</item>
<item>
<title>Shuttle Executes LOI with Molecule.ai</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-executes-loi-molecule-ai-142000575</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-executes-loi-molecule-ai-142000575</guid>
<pubDate>Fri, 10 Oct 2025 14:20:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today announced the execution of a non-binding letter of Intent with Molecule.ai. Molecule.ai, a pioneering artificial intelligence company founded by AI scientist and researcher Dr. ZT Zhang, PhD, today announced the execution of a letter of Intent to acquire Molecule.ai and its state-o</description>
</item>
<item>
<title>Shuttle to Enter $3.24 Billion AI Pharmaceutical Market</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-enter-3-24-billion-201500144</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-enter-3-24-billion-201500144</guid>
<pubDate>Thu, 09 Oct 2025 20:15:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today announced the execution of a non-binding letter of Intent with Molecule.ai. Molecule.ai, a pioneering artificial intelligence company founded by AI scientist and researcher Dr. ZT Zhang, PhD, today announced the execution of a letter of Intent to acquire Molecule.ai and its state-o</description>
</item>
<item>
<title>Shuttle Pharma Provides Second Quarter 2025 Corporate Update</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-provides-second-quarter-200500505</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-provides-second-quarter-200500505</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Recent Activities: Patient enrollment in the Company’s Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma reached 63% in the initial</description>
</item>
<item>
<title>Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-closing-4-201000383</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-closing-4-201000383</guid>
<pubDate>Tue, 24 Jun 2025 20:10:00 GMT</pubDate>
<description>GAITHERSBURG, Md., June 24, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before de</description>
</item>
<item>
<title>Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-pricing-4-195500649</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharmaceuticals-announces-pricing-4-195500649</guid>
<pubDate>Fri, 20 Jun 2025 19:55:00 GMT</pubDate>
<description>GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other off</description>
</item>
<item>
<title>Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-announces-reverse-stock-160000487</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-announces-reverse-stock-160000487</guid>
<pubDate>Thu, 12 Jun 2025 16:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m., Eastern Time. The Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under</description>
</item>
<item>
<title>Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-announces-proposed-reverse-123000785</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-announces-proposed-reverse-123000785</guid>
<pubDate>Thu, 12 Jun 2025 12:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved,</description>
</item>
<item>
<title>Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-appoints-george-scorsis-200100408</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-appoints-george-scorsis-200100408</guid>
<pubDate>Wed, 04 Jun 2025 20:01:00 GMT</pubDate>
<description>GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of exper</description>
</item>
<item>
<title>Shuttle Pharma Provides Corporate Update</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-provides-corporate-204500908</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-provides-corporate-204500908</guid>
<pubDate>Thu, 15 May 2025 20:45:00 GMT</pubDate>
<description>GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Shuttle Pharma’s recent highlights: Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma highlights include: Patient enrollment nears mi</description>
</item>
<item>
<title>Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-fda-orphan-drug-200100735</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-fda-orphan-drug-200100735</guid>
<pubDate>Thu, 08 May 2025 20:01:00 GMT</pubDate>
<description>GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatmen</description>
</item>
<item>
<title>Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-present-planet-microcap-201500782</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-present-planet-microcap-201500782</guid>
<pubDate>Mon, 21 Apr 2025 20:15:00 GMT</pubDate>
<description>Company to conduct 1x1 meetings on April 24, 2025GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at</description>
</item>
<item>
<title>Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer</title>
<link>https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-developing-pretreatment-diagnostic-200100665</link>
<guid isPermaLink="true">https://6ix.com/company/shuttle-pharmaceuticals-inc/news/shuttle-pharma-developing-pretreatment-diagnostic-200100665</guid>
<pubDate>Thu, 10 Apr 2025 20:01:00 GMT</pubDate>
<description>Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs Dr. Alan Kozikowski, internationally acclaimed pioneer in the discovery of a critical PSMA targeting ligand for clinical applications is co-inventor Theranostic molecule designed to preferentially target prostate cancer cells to the effects of radiation and chemotherapeutic agents GAITHERSBURG, Md., April 10</description>
</item>
</channel>
</rss>